Clinical Trials / Studies – Still Enrolling


Canine Osteosarcoma Vaccine

*NEW* We are now enrolling dogs with osteosarcoma who have undergone amputation and chemotherapy in a study of the Canine Osteosarcoma Vaccine, Live Listeria Vector (COV-LLV), a conditionally licensed product. All dogs enrolled in the study will be treated with the vaccine.

--Please contact the Medical Oncology service at 858-875-7500 for more information. 

Dogs with untreated multicentric lymphoma evaluating the response rate of single-agent procarbazine.

*NEW* Dogs must be asymptomatic and have a histologic or cytologic diagnosis of intermediate or high grade multicentric lymphoma confirmed prior to presentation. Patients must not have received prior chemotherapy or steroid therapy and cannot have T cell lymphoma (typing costs covered by the study; if T cell already diagnosed elsewhere, patient is not eligible). Owners will be financially responsible for the cost of the initial oncology consultation, all other routine chemotherapy-related expenses are covered for the duration of the trial. 

--Please call Drs. Brenda Phillips or Samantha Bajorek at (858) 875-7500 at Sorrento Valley or Drs. Andi Flory or Mairin Miller at (760) 466-0600 at North County

Trial evaluating a novel immunotherapy protocol for canine splenic hemangiosarcoma.

FULLY ENROLLED/CLOSED -  Fully funded OTHER THAN SPLENECTOMY including pre-operative labwork and thoracic radiographs. Patient consult should ideally occur with Oncologist prior to splenectomy as tumor tissue must be collected using special procedures. However, it is possible for emergent informed consent to take place with slightly delayed tissue preparation for after-hours ER cases.

--Please call Dr. Brenda Phillips 858-875-7500 or Dr Andi Flory 760-466-0600.  

Dogs with Hemangiosarcoma: Precision Medicine/Genomic Characterization Study

FULLY ENROLLED/CLOSED - Eligibility Criteria: Dogs that have hemoabdomen due to a mass on the spleen that undergo splenectomy. Owners must be agreeable to splenectomy at VSH, willing to come to VSH for re-staging every 2 months for 1 year (no charge to the owner). Any therapy choices will be completely at the owner’s discretion. This study provides $1000 off of the cost for splenectomy, extensive staging every 2 months for 1 year at no cost to the client (CBC, Chem panel, UA, thoracic radiographs, abdominal ultrasound exam) and a Precision Medicine genomic report to aide in drug selection (though any treatment is completely at the owner’s discretion).

--Contact Drs. Brenda Phillips, Fred Pike, Andi Flory and Stephanie Istvan at (858) 875-7500 in Sorrento Valley, or Dr. Andi Flory and Kate Wotrang, at (760) 466-0600 in North County.  


Melanoma and Mast Cell Tumors 

A funded clinical trial to evaluate a novel immunotherapy in dogs with melanoma and mast cell tumors

*NOTE*   Both Trials are now fully enrolled.

Trial Specifics:

This trial is designed to evaluate the safety and preliminary anti-cancer activity of a novel, monoclonal antibody in dogs with measurable cancer.  An estimated 20 client-owned dogs with Melanoma or Mast Cell Tumors will be enrolled.  The antibody is administered IV by the study staff every 14 days for up to 10 treatments.  No placebo is used in this trial. Visits will be required every 2 weeks for a total trial period of 140 days. 

Trial Funding:

The trial is fully funded for the full trial duration (140 days), including the antibody and trial-related procedures.  

Trial Eligibility:

Dogs with one of the following cancers may be enrolled if they meet the specific criteria for each cancer:

Mast Cell Tumors - CLOSED - Fully enrolled

  • At least one measurable skin tumor +/- metastatic lymph node(s) > 2 cm
  • No intraabdominal metastasis
  • Prior therapy accepted with washout times to be discussed with the participating site

Melanoma - CLOSED - Fully enrolled

  • At least one measurable malignant tumor in the oral cavity, digit, skin +/- metastatic lymph node > 2 cm
  • No pulmonary metastasis
  • Prior therapy accepted with washout times to be discussed with site

For details please call Oncology Services at 858.875-7500. 

Canine Osteosarcoma 

This trial is now fully enrolled & closed. Canine osteosarcoma, fully funded trial evaluating a novel immunotherapy procedure. Either Sorrento Valley or San Marcos hospitals. A pre-amputation consult is required but a pre-consult histologic/cytologic diagnosis is not necessary.

--Please call Oncology Services at (858) 875-7500 or (760) 466-0600 with any questions.


Clinical Trial for Atopic Dogs

*NEW* Dr. Laura Stokking is enrolling canine patients in a new clinical trial for atopic dogs. Patients cannot have had any long-acting treatments for allergy, such as glucocorticoid injections or Cytopoint. Food allergy should have been ruled out prior to enrollment.

--For more information please contact Dermatology at (858) 875-7500. 

Emergency & Critical Care

Novel Rattlesnake Antivenom

*NEW* We are currently enrolling dogs that have been bitten (or suspected to have been bitten) by a rattlesnake for treatment with a novel antivenom. Enrolled dogs will receive free bloodwork on presentation (CBC, chemistry, coagulation panel) and trial antivenom at no cost to the client. Patients are required to return for a 24 hour post-antivenom administration recheck and free bloodwork (CBC, chemistry, coagulation panel). Owners must commit to the 24 hour recheck as well as use of their pet’s photos and/or videos for research and publication purposes. Patients are now being enrolled at Sorrento Valley, and North County enrollment begins August 14.

--For more information please contact Emergency and Critical Care at (858) 875-7500. 

Internal Medicine

Canine Bile Acid Diarrhea and Microbial Dysbiosis Study

*NEW* We are enrolling dogs with signs of inflammatory bowel disease, with or without histopathologic evidence, that are on current standard therapies (prednisone, diet) but continue to have diarrhea. A GI panel and fecal analysis for bile acid concentration and enteropathogens, along with a dysbiosis index will be performed through the GI Lab at Texas A&M. Dogs with a non-GI disease to explain their sign will be excluded. Patients will be randomly assigned into a placebo or cholestyramine group. Owners will be asked to grade their dog’s feces daily. Dogs will be re-evaluated at 3, 6, and 16 weeks post induction of therapies. At these rechecks, a fecal sample will be collected and submitted for a fecal bile acid analysis and microbial evaluation. All study related expenses will be funded. Cost to initial diagnosis of a chronic enteropathy will be covered by clients.

--Contact Internal Medicine Service (858) 875-7500

Clinical Trial for Diabetic Dogs

VSH is participating in an exciting new clinical trial using a novel stem cell therapy to resolve diabetes mellitus in dogs! Dogs must weigh 5 to 12 kg, and be free of significant other systemic illnesses, on insulin (preferably Vetsulin), and at least partially controlled. Owners must be willing to perform glucose curves at home (with training), and to reliably bring the dog in for follow-up visits over 3 years. All study-associated costs are covered for the study duration (labs, procedures, insulin, glucometer, exams, etc.), including the initial screening visit, so we encourage any potential candidates to come in for formal screening with Drs. Loy Son, Gil, Dong, or Fischer.

--Click here for additional details or call (858) 875-7500.

Glomerular Disease Study

VSH is participating in a multi-center prospective study evaluating increased dosing of enalapril in dogs with glomerular disease. Client incentives include reduced cost of some initial testing and no cost for scheduled recheck visits and tests.

--For more information please contact Internal Medicine at (858) 875-7500.


Novel Rattlesnake Antivenom

*NEW* Clinical trial on tarsal replacement surgery. Dogs greater than 30kg with end stage osteoarthritis of the Tarsus.

--For more information please contact Surgery at (858) 875-7500. 

For a list of clinical trials across the Nation go to